Kawinthra Khwanraj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kawinthra Khwanraj has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Athinan Prommahom
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand, mahidol.ac.th
1 shared publication - Athinan Prommahom
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University Samut Prakan Thailand
1 shared publication Atipha Kijkraikul
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
1 shared publicationChonlakorn Panyasuppakun
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
1 shared publicationPermphan Dharmasaroja
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
1 shared publication- Permphan Dharmasaroja
Department of Anatomy, Faculty of Science, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in The Scientific World Journal
- Vol. 2026 (1) , e4373377
The Multifaceted Roles of Eukaryotic Elongation Factor 1‐Alpha‐2 in Neurodevelopmental and Neurodegenerative Disorders
Eukaryotic elongation factor 1‐alpha‐2 (eEF1A2) is a neuron‐ and muscle‐specific translation elongation factor isoform that supports high‐demand proteostasis in terminally differentiated cells. Beyond its canonical role in translation elongation, eEF1A2 participates in noncanonical processes linked to actin cytoskeleton regulation, compartmentalized/local translation, and stress–response signaling. A central challenge in the field is that the strength and type of evidence implicating eEF1A2 differ substantially across disease classes. In neurodevelopmental disorders, heterozygous de novo pathogenic variants in EEF1A2 provide strong causal human genetic evidence for developmental and epileptic encephalopathies and related phenotypes, supported by functional studies showing reduced de novo protein synthesis/elongation and altered actin bundling in common patient‐associated variants. In contrast, in neurodegenerative paradigms (e.g., toxin‐based Parkinson′s disease models and ischemia‐reperfusion injury), eEF1A2 is primarily implicated as a contributory node within oxidative stress, autophagy/mitophagy, and inflammatory signaling pathways, largely based on cellular and animal model evidence rather than Mendelian causality. This review adopts an evidence‐based framework and organizes findings around a unified mechanistic model connecting canonical elongation and noncanonical cytoskeleton/stress/autophagy functions to neuronal phenotypes. Collectively, current evidence supports a causal role for eEF1A2 in neurodevelopmental disorders but only a contributory role in neurodegenerative conditions.
- 1 January 2026
- Published by Wiley in The Scientific World Journal
- Vol. 2026 (1) , e4373377
Open AccessThe Multifaceted Roles of Eukaryotic Elongation Factor 1‐Alpha‐2 in Neurodevelopmental and Neurodegenerative Disorders
Eukaryotic elongation factor 1‐alpha‐2 (eEF1A2) is a neuron‐ and muscle‐specific translation elongation factor isoform that supports high‐demand proteostasis in terminally differentiated cells. Beyond its canonical role in translation elongation, eEF1A2 participates in noncanonical processes linked to actin cytoskeleton regulation, compartmentalized/local translation, and stress–response signaling. A central challenge in the field is that the strength and type of evidence implicating eEF1A2 differ substantially across disease classes. In neurodevelopmental disorders, heterozygous de novo pathogenic variants in EEF1A2 provide strong causal human genetic evidence for developmental and epileptic encephalopathies and related phenotypes, supported by functional studies showing reduced de novo protein synthesis/elongation and altered actin bundling in common patient‐associated variants. In contrast, in neurodegenerative paradigms (e.g., toxin‐based Parkinson′s disease models and ischemia‐reperfusion injury), eEF1A2 is primarily implicated as a contributory node within oxidative stress, autophagy/mitophagy, and inflammatory signaling pathways, largely based on cellular and animal model evidence rather than Mendelian causality. This review adopts an evidence‐based framework and organizes findings around a unified mechanistic model connecting canonical elongation and noncanonical cytoskeleton/stress/autophagy functions to neuronal phenotypes. Collectively, current evidence supports a causal role for eEF1A2 in neurodevelopmental disorders but only a contributory role in neurodegenerative conditions.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 17, 687-705
Neuroprotective Effects of Asiatic Acid on Autophagy and Mitochondrial Integrity in a Parkinson’s Disease Cellular Model
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder. PD patients mostly exhibit mitochondrial dysfunction and autophagic impairment. Asiatic acid (AA) is a triterpenoid with the highest antioxidant activity used to treat oxidative stress. It has been found to have a neuroprotective effect against mitochondrial dysfunction in cellular models of PD; however, its effect on autophagy has not been investigated. Purpose: This study aimed to investigate whether AA affects autophagy in a cellular model of PD. Methods: SH-SY5Y cells were differentiated into dopaminergic neuron-like cells via retinoic acid administration. Differentiated cells were treated with AA for 24 h and then exposed to 1-methyl-4-phenylpyridinium (MPP+). Cell viability was assessed using a 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay. The expression of microtubule-associated protein 1 light chain 3 (LC3)-II/I, Beclin-1, sequestosome-1/ubiquitin-binding protein p62 (SQSTM1/p62), and tyrosine hydroxylase (TH) was analyzed via Western blot. Caspase-3/7 and LC3 expression was measured using immunofluorescence, as was the colocalization of LC3 and mitochondria. MitoTracker and JC-10 were used to assess the mitochondrial morphology and mitochondrial membrane potential (ΔΨm), respectively. Results: Pretreating cells with AA before MPP+ exposure resulted in significantly higher expression of LC3-II/I and Beclin-1, while the expression of SQSTM1/p62 was slightly lower compared to that in cells not pretreated with AA. Cells pretreated with AA exhibited significantly higher viability and TH expression, but significantly lower caspase-3/7 expression and numbers of apoptotic nuclei compared to cells treated with MPP+ alone. Notably, pretreatment with AA resulted in tubular mitochondria with considerably higher ΔΨm values. The colocalization of LC3 and mitochondria was also significantly higher in the cells pretreated with AA. Conclusion: AA protected dopaminergic neuron-like cells against MPP+-induced apoptosis via the induction of autophagy and the enhancement of mitochondrial function, suggesting that it could be developed as a therapeutic agent for PD.
- 1 October 2025
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 17, 687-705
Open AccessNeuroprotective Effects of Asiatic Acid on Autophagy and Mitochondrial Integrity in a Parkinson’s Disease Cellular Model
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder. PD patients mostly exhibit mitochondrial dysfunction and autophagic impairment. Asiatic acid (AA) is a triterpenoid with the highest antioxidant activity used to treat oxidative stress. It has been found to have a neuroprotective effect against mitochondrial dysfunction in cellular models of PD; however, its effect on autophagy has not been investigated. Purpose: This study aimed to investigate whether AA affects autophagy in a cellular model of PD. Methods: SH-SY5Y cells were differentiated into dopaminergic neuron-like cells via retinoic acid administration. Differentiated cells were treated with AA for 24 h and then exposed to 1-methyl-4-phenylpyridinium (MPP+). Cell viability was assessed using a 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay. The expression of microtubule-associated protein 1 light chain 3 (LC3)-II/I, Beclin-1, sequestosome-1/ubiquitin-binding protein p62 (SQSTM1/p62), and tyrosine hydroxylase (TH) was analyzed via Western blot. Caspase-3/7 and LC3 expression was measured using immunofluorescence, as was the colocalization of LC3 and mitochondria. MitoTracker and JC-10 were used to assess the mitochondrial morphology and mitochondrial membrane potential (ΔΨm), respectively. Results: Pretreating cells with AA before MPP+ exposure resulted in significantly higher expression of LC3-II/I and Beclin-1, while the expression of SQSTM1/p62 was slightly lower compared to that in cells not pretreated with AA. Cells pretreated with AA exhibited significantly higher viability and TH expression, but significantly lower caspase-3/7 expression and numbers of apoptotic nuclei compared to cells treated with MPP+ alone. Notably, pretreatment with AA resulted in tubular mitochondria with considerably higher ΔΨm values. The colocalization of LC3 and mitochondria was also significantly higher in the cells pretreated with AA. Conclusion: AA protected dopaminergic neuron-like cells against MPP+-induced apoptosis via the induction of autophagy and the enhancement of mitochondrial function, suggesting that it could be developed as a therapeutic agent for PD.